Diabetes drugs for nonalcoholic fatty liver disease: a systematic review
ConclusionsConsistent with existing clinical practice guidelines, which recommend lifestyle intervention and treatment for comorbidities related to fatty liver disease as first-line treatment, trial evidence supports the efficacy of some diabetes drugs (especially pioglitazone) in patients with NAFLD or NASH, though weight gain with some diabetes drugs may warrant caution. Larger trials are needed to better characterize the efficacy and harms of diabetes pharmacotherapy in these patients.
Source: Systematic Reviews - Category: International Medicine & Public Health Source Type: research
More News: Actos | Byetta | Databases & Libraries | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Fortamet | Hypertension | International Medicine & Public Health | Liver | Liver Disease | Metabolic Syndrome | Metformin | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Study | Urology & Nephrology | Victoza